Loading...
XSHG603351
Market cap420mUSD
Jan 09, Last price  
22.75CNY
1D
2.20%
1Q
-0.39%
IPO
-26.94%
Name

Nanjing Well Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603351 chart
P/E
27.46
P/S
2.67
EPS
0.83
Div Yield, %
1.73%
Shrs. gr., 5y
6.68%
Rev. gr., 5y
7.60%
Revenues
1.16b
+4.03%
527,598,124498,690,763558,443,860694,110,645801,451,310880,756,050736,063,7481,042,305,9151,111,010,6821,155,839,776
Net income
112m
+18.07%
44,827,77260,671,29473,674,043107,432,216111,814,351128,107,850100,446,704101,370,20495,028,722112,199,192
CFO
120m
+10.33%
74,615,18581,135,872128,181,46671,271,47463,758,147129,694,09993,304,3520108,989,026120,243,703
Dividend
Jun 13, 20240.3 CNY/sh
Earnings
May 16, 2025

Profile

Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables. The company also provides synthetic base oils, such as hydraulic fluids, lubricity additives for metals, metal quenching, base fluids and lubricity additives, synthetic base for compress lubricants, synthetic base oil for gear, base oil of chain lubricants, base stock of engine oil, base stock of heat transfer oil, and base oil of grease; and other products, including painting and coating, textile chemicals, field chemicals, and low foam metal cleaners. It also exports its products to Europe, the United States, Southeast Asia, and internationally. The company was formerly known as Nanjing Well Pharmaceutical Co.,Ltd. and changed its name to Nanjing Well Pharmaceutical Group Co.,Ltd. in April 2020. The company was founded in 2000 and is based in Nanjing, China.
URL
http://www.well-js.com/
IPO date
Jan 30, 2019
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,155,840
4.03%
1,111,011
6.59%
Cost of revenue
951,019
927,712
Unusual Expense (Income)
NOPBT
204,821
183,298
NOPBT Margin
17.72%
16.50%
Operating Taxes
12,327
18,419
Tax Rate
6.02%
10.05%
NOPAT
192,494
164,880
Net income
112,199
18.07%
95,029
-6.26%
Dividends
(53,415)
(40,644)
Dividend yield
1.50%
1.42%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
382,894
369,676
Long-term debt
122,828
72,769
Deferred revenue
12,711
6,500
Other long-term liabilities
1
Net debt
276,884
273,823
Cash flow
Cash from operating activities
120,244
108,989
CAPEX
(73,071)
Cash from investing activities
Cash from financing activities
4,791
161,195
FCF
48,233
(128,289)
Balance
Cash
158,798
100,934
Long term investments
70,040
67,688
Excess cash
171,047
113,071
Stockholders' equity
603,156
595,756
Invested Capital
1,921,303
1,777,048
ROIC
10.41%
9.95%
ROCE
9.73%
9.63%
EV
Common stock shares outstanding
135,180
132,591
Price
26.37
21.91%
21.63
-44.78%
Market cap
3,564,690
24.29%
2,867,952
-43.97%
EV
3,849,832
3,143,887
EBITDA
276,557
255,056
EV/EBITDA
13.92
12.33
Interest
15,516
11,177
Interest/NOPBT
7.58%
6.10%